s S197 technically demanding HTx operation and that longer duration would have a higher incidence of post-operative vasoplegia. Methods: All patients who received a CF-LVAD for BTT at our center from 01/08-09/14 were evaluated (n= 116). Eighty (69%) patients underwent HTx, 12 (10%) died before HTx, and 24 (21%) remain listed for HTx and continue on LVAD support. Of the 80 transplanted patients, 29 (36%) were supported with an LVAD for ≤ 180 days (group 1) and 51 (64%) for > 180 days (group 2). Results: Mean time of LVAD support was 98±41 d for group 1 and 365±193 for group 2. Mean age for group 1 was 52±9 years vs 57±9 for group 2 (p= 0.02). Median operative time (473 vs 523 min), CPB time (205 vs. 219 min), aortic cross clamp time (119 vs 126 min) and intra-operative blood product transfusion (6 vs 6.3 units) did not differ between groups (p> 0.05). While median ICU time (88 vs 92 hrs) and the degree or duration of vasoconstrictor support after HTx were similar, there was a trend for prolonged ventilation (> 24h) in group 2 (24% vs 10%; p= 0.06). Median hospital length of stay was 9 d for both groups. Survival after HTx at 1 and 3 years was 93% for group 1 and 91% and 87% for group 2, respectively (Figure; Log rank p= 0.57). Conclusion: Shorter duration of CF-LVAD support does not appear to increase the technical difficulty of HTx operation and longer duration of support was not associated with a greater incidence of vasoplegia. Both groups had equivalent and excellent long-term survival.